In the last decade, two classes of anti-diabetic drugs, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have attracted scientific interest due to their impressive cardiovascular benefits in AMI patients with and without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.